Flow chart of patient recruitment.

<p>Flow chart of patient recruitment.</p

Patient characteristics per recurrence of venous thromboembolism.

<p>OAC, oral anticoagulation; DVT, deep venous thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism. Data are given as number of observations (n) and percentage of total (%) or median with interquartile range. P-values refer to group comparison.</p><p>Patient characteristics per recurrence of venous thromboembolism.</p

Risk of recurrence of venous thromboembolism with depressive symptoms.

<p>Depressive symptoms were entered in steps of 3 points. The model accounted for 10.5% of the variance (chi square = 13.99, df = 5, p = 0.016).</p><p>Risk of recurrence of venous thromboembolism with depressive symptoms.</p

Supplemental Material, Supplementary_Table_758956 - Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study

<p>Supplemental Material, Supplementary_Table_758956 for Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study by Giuseppe Colucci, Karin Helsing, Franziska Demarmels Biasiutti, Luigi Raio, Pirmin Schmid, Dimitrios A. Tsakiris, Balthasar Eberle, Daniel Surbek, Bernhard Lämmle, and Lorenzo Alberio in Clinical and Applied Thrombosis/Hemostasis</p

Association of ceDNA, circulating nucleosomes, and NETs with VTE extent.

<p><b>(A)</b> CeDNA and (<b>B</b>) circulating nucleosomes in plasma correlated with the extent of VTE. (<b>C</b>) Plasma levels of the NET-specific biomarker, DNA-histone-MPO complexes, did not significantly correlate with VTE extent. Extent of acute VTE was categorized as isolated distal DVT only (n = 51), proximal DVT ± distal DVT (n = 133), and PE ± DVT (n = 427). All VTE (n = 611). FU: Fluorescent units; OD: Optical density. Data is shown as median ± inter-quartile range. P-values were calculated using a nonparametric test for trend across ordered groups.</p

Characterization of VTE patients.

<p>Characterization of VTE patients.</p

Association of ceDNA with comorbidities.

<p>Association of ceDNA with comorbidities.</p

Association of log-transformed ceDNA with 3-month mortality.

<p>Association of log-transformed ceDNA with 3-month mortality.</p

Comparison of the ceDNA to laboratory markers of inflammation and thrombosis for the prediction of 3-month-mortality.

<p>Area under the curve (AUC) from ROC analysis of ceDNA, us-CRP, leukocyte count, D-dimer, platelet count shows ceDNA and usCRP to be strong predictors of 3-months mortality following acute VTE.</p

Association of ceDNA with VTE recurrence and mortality during follow-up.

<p>Association of ceDNA with VTE recurrence and mortality during follow-up.</p